The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, discusses the complexities of biomarker-guided treatment in chronic lymphocytic leukemia (CLL), highlighting the importance of various prognostic and predictive biomarkers, including genetic mutations like TP53 and NOTCH1. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Newave, Loxo, Beigene, AstraZeneca, Abbvie, Janssen, Pharmacyclics; Research Funding; Schrodinger, Morphosys, Karyopharm, Janssen, Pharmacyclics.
